Literature DB >> 3611053

End products of glucose and glutamine metabolism by L929 cells.

K W Lanks.   

Abstract

Products of glucose and glutamine metabolism by L929 cells were detected and quantitated by gas chromatography and mass spectrometry of the oxime-trimethylsilyl derivatives. This method allowed detection and identification of all major carboxylic and amino acids produced in the system. Although lactic acid was expected to be the major product, alanine, citric, glutamic, aspartic, and pyruvic acids were also released into the culture medium at significant rates. Incorporation of labeled carbon from D-[U-13C]glucose showed that the alanine, lactic, and pyruvic acids were derived from glucose as was one-third of the citric acid carbon. The rate of glucose utilization for production of these end products was 29-fold greater than the rate of glucose oxidation to CO2, and calculated ATP production from alanine and pyruvate synthesis exceeded that from lactate synthesis by nearly 2-fold. Utilization of glutamine for synthesis of aspartic, glutamic, and citric acids also exceeded the rate of glutamine oxidation, thereby making end-product synthesis from glucose and glutamine the dominant cellular metabolic activity. In the absence of glucose, synthesis and intracellular levels of aspartic and glutamic acids increased, whereas synthesis and cell content of the other acids decreased markedly. This response is consistent with the metabolic pattern proposed by Moreadith and Lehninger (Moreadith, R.W., and Lehninger, A.L. (1984) J. Biol. Chem. 259, 6215-6221) in which much of the glutamine used by these cells is converted to aspartate in the absence of a pyruvate source and to aspartate or citrate in the presence of pyruvate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3611053

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Methods and strategies available for the process control and optimization of monoclonal antibody production.

Authors:  P Fu; J P Barford
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

2.  Glutamine metabolism in skeletal muscles from the broiler chick (Gallus domesticus) and the laboratory rat (Rattus norvegicus)

Authors:  G Y Wu; J R Thompson; V E Baracos
Journal:  Biochem J       Date:  1991-03-15       Impact factor: 3.857

Review 3.  The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.

Authors:  S Mazurek; C B Boschek; E Eigenbrodt
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

Review 4.  Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies.

Authors:  L G Baggetto
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

5.  A 1H/15N n.m.r. study of nitrogen metabolism in cultured mammalian cells.

Authors:  J C Street; A M Delort; P S Braddock; K M Brindle
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

6.  The role of reduced nicotinamide adenine dinucleotide phosphate in glucose- and temperature-dependent doxorubicin cytotoxicity.

Authors:  J P Gao; S Friedman; K W Lanks
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Chinese hamster ovary cell growth and interferon production kinetics in stirred batch culture.

Authors:  P M Hayter; E M Curling; A J Baines; N Jenkins; I Salmon; P G Strange; A T Bull
Journal:  Appl Microbiol Biotechnol       Date:  1991-02       Impact factor: 4.813

8.  Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma.

Authors:  Boris Ratnikov; Pedro Aza-Blanc; Ze'ev A Ronai; Jeffrey W Smith; Andrei L Osterman; David A Scott
Journal:  Oncotarget       Date:  2015-04-10

Review 9.  Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.

Authors:  Diana Cervantes-Madrid; Yair Romero; Alfonso Dueñas-González
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.